Want to join the conversation?
$WAT, which competes with $PKI and $TMO, said the company's pharmaceutical market led the way with 12% growth in 2Q16. The company saw good growth in its core small molecule QA/QC as well as in large molecule R&D oriented applications. On product line dynamics, instrument sales grew 7% with positive demand for core LC and bench top LC-MS platforms.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.